ABN Amro Investment Solutions Acquires 126,088 Shares of Boston Scientific Corporation $BSX

Posted by Brenda Bartman on May 21st, 2026

Boston Scientific logo ABN Amro Investment Solutions boosted its holdings in Boston Scientific Corporation (NYSE:BSX – Free Report) by 22.5% during the 4th quarter, Holdings Channel.com reports. The fund owned 687,007 shares of the medical equipment provider’s stock after purchasing an additional 126,088 shares during the quarter. Boston Scientific accounts for 1.0% of ABN Amro Investment Solutions’ investment portfolio, making the stock its 23rd biggest holding. ABN Amro Investment Solutions’ holdings in Boston Scientific were worth $65,506,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Rathbones Group PLC increased its stake in Boston Scientific by 20.9% in the 4th quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock valued at $263,133,000 after buying an additional 477,680 shares during the last quarter. Little House Capital LLC grew its stake in Boston Scientific by 34.7% in the 4th quarter. Little House Capital LLC now owns 13,373 shares of the medical equipment provider’s stock valued at $1,275,000 after buying an additional 3,443 shares in the last quarter. Atle Fund Management AB grew its stake in Boston Scientific by 25.4% in the 4th quarter. Atle Fund Management AB now owns 108,682 shares of the medical equipment provider’s stock valued at $10,363,000 after buying an additional 22,002 shares in the last quarter. Fairtree Asset Management Pty Ltd purchased a new position in Boston Scientific in the 4th quarter valued at approximately $1,171,000. Finally, Harvest Portfolios Group Inc. grew its stake in Boston Scientific by 6.1% in the 4th quarter. Harvest Portfolios Group Inc. now owns 597,341 shares of the medical equipment provider’s stock valued at $56,956,000 after buying an additional 34,598 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on BSX shares. Bank of America reduced their price objective on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a research note on Monday. Royal Bank Of Canada reduced their price objective on shares of Boston Scientific from $105.00 to $100.00 and set an “outperform” rating for the company in a research note on Thursday, April 23rd. Canaccord Genuity Group reduced their price objective on shares of Boston Scientific from $109.00 to $71.00 and set a “buy” rating for the company in a research note on Thursday, April 23rd. TD Cowen reduced their price objective on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a research note on Monday, February 2nd. Finally, The Goldman Sachs Group reduced their price objective on shares of Boston Scientific from $87.00 to $84.00 and set a “buy” rating for the company in a research note on Wednesday, April 22nd. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $92.71.

View Our Latest Analysis on Boston Scientific

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

Positive Sentiment: Boston Scientific reported positive pivotal results for its SEISMIQ 4CE coronary intravascular lithotripsy catheter in the FRACTURE trial, meeting key safety and effectiveness endpoints in patients with severely calcified coronary artery disease. The company plans to use the data to support a regulatory filing, which strengthens its cardiovascular pipeline and could expand future revenue. Article Title
Positive Sentiment: The company announced a $2 billion accelerated share repurchase and a broader $5 billion buyback authorization, signaling confidence in its valuation and providing support for earnings per share over time. Article Title
Positive Sentiment: Boston Scientific also invested $1.5 billion for an equity stake in MiRus, with an option tied to the company’s TAVR business, which could deepen BSX’s position in structural heart and create an additional growth path. Article Title
Neutral Sentiment: Baird lowered its price target on BSX to $75 from $78 but kept an Outperform rating, suggesting analysts remain constructive even after revising near-term expectations lower. Article Title
Neutral Sentiment: Other recent broker updates were mixed, with some firms reaffirming Buy ratings while Bank of America also trimmed its target, keeping the analyst backdrop supportive but not especially strong. Article Title
Negative Sentiment: Some market commentary and fund commentary referenced BSX as having “weak results” or falling on that basis, which adds to the perception of recent pressure on the shares. Article Title

Boston Scientific Price Performance

NYSE:BSX opened at $56.59 on Thursday. The firm has a market capitalization of $84.11 billion, a price-to-earnings ratio of 23.68, a P/E/G ratio of 1.04 and a beta of 0.62. Boston Scientific Corporation has a 52-week low of $52.52 and a 52-week high of $109.50. The stock has a fifty day moving average of $62.46 and a 200 day moving average of $80.71. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90.

Boston Scientific (NYSE:BSX – Get Free Report) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.01. The company had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm’s quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter last year, the company earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, research analysts expect that Boston Scientific Corporation will post 3.38 EPS for the current fiscal year.

Boston Scientific announced that its board has initiated a stock buyback plan on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board believes its shares are undervalued.

Boston Scientific Profile

(Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.